Anti-Human VEGF (Fab) (Ranibizumab Biosimilar)
英诺赛图(InnoCyto)的 Anti-Human VEGF (Fab) (Ranibizumab Biosimilar)(克隆 Ranibizumab) 为人源 IgG1 抗体,靶向 Human,适用于流式细胞术。提供 2 mg、10 mg 规格,目录价 ¥3,390 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 Anti-Human VEGF (Fab) (Ranibizumab Biosimilar)(克隆 Ranibizumab) 为人源 IgG1 抗体,靶向 Human,适用于流式细胞术。提供 2 mg、10 mg 规格,目录价 ¥3,390 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
505101 | 2 mg | ¥3,390
505102 | 10 mg | ¥8,475
Product Details
Product Description|Anti-Human VEGF (Fab) (Ranibizumab Biosimilar)
Regulatory Status|RUO
Species specificity|Human
Storage Conditions|4ºC
Maximal Shelf Life|12 months
Target Name|Vascular endothelial growth factor, VEGF-A, VEGFA, VEGF
See All Formats|Clone Ranibizumab
Background Information
Ranibizumab is a recombinant humanized monoclonal antibody fragment (Fab) designed to specifically bind and neutralize vascular endothelial growth factor A (VEGF-A). Structurally, it is a single antigen-binding fragment derived from the same parent murine antibody as bevacizumab but lacks the Fc (fragment crystallizable) region, which distinguishes it from full-length immunoglobulin G (IgG) antibodies. The absence of the Fc domain results in a smaller, monovalent molecule with a molecular weight of approximately 48 kilodaltons (kDa).
The molecular structure of Ranibizumab comprises a variable heavy (VH) domain and a variable light (VL) domain connected to their respective constant regions (CH1 and CL). Together, these domains form a single high-affinity antigen-binding site, with complementarity-determining regions (CDRs) mediating specific binding to VEGF-A isoforms, including VEGF121, VEGF165, and VEGF189. The CDRs establish strong non-covalent interactions with residues located within the heparin-binding domain of VEGF-A. This high-affinity binding occurs in the picomolar range, effectively sequestering VEGF-A and preventing it from binding to its cell surface receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR). The disruption of VEGF-receptor interactions inhibits downstream receptor dimerization and phosphorylation, blocking intracellular signaling pathways such as MAPK and PI3K-AKT that mediate vascular permeability, endothelial proliferation, and angiogenesis in experimental systems.
Functionally, Ranibizumab’s small molecular size enhances tissue penetration and allows rapid diffusion through extracellular matrices, making it suitable for localized VEGF inhibition at target sites. Although it lacks the Fc fragment, and thus cannot engage Fc gamma receptors (FcγRs) or activate complement, it retains high structural stability and solubility due to optimized domain folding and disulfide bridge formation. Overall, Ranibizumab exemplifies precision antibody engineering, combining molecular compactness and epitope specificity to investigate VEGF-mediated signaling and angiogenic processes in molecular biology research.
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). Anti-Human VEGF (Fab) (Ranibizumab Biosimilar)(505101)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-vegf-fab-ranibizumab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human VEGF (Fab) (Ranibizumab Biosimilar)(505101). 产品目录. https://www.suprotek.cn/products/item/anti-human-vegf-fab-ranibizumab-biosimilar.html
@misc{biocsp_item_anti_human_vegf_fab_ranibizumab_biosimilar,
title = {Anti-Human VEGF (Fab) (Ranibizumab Biosimilar)(505101)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/anti-human-vegf-fab-ranibizumab-biosimilar.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源